Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-
altering. We initiated a phase 2 study in which patients with MIBC received four cycles of …

Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …

We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized
by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the …

PURPOSE Novel sensitive methods for early detection of relapse and for monitoring
therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately …

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

Background An early report on the molecular subtyping of muscle-invasive bladder cancer
(MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …

DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …